Aggressive Fibromatosis Market
Number of pages: 100 | Report Format: PDF | Published date: March 31, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.48 billion |
|
Revenue Forecast in 2031 |
US$ 4.61 billion |
|
CAGR |
7.10% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment Type, Patient Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global aggressive fibromatosis market was valued at US$ 2.48 billion in 2022 and is expected to register a revenue CAGR of 7.10% to reach US$ 4.61 billion by 2031.
Aggressive Fibromatosis Market Fundamentals
Aggressive fibromatosis is a tumor type typically seen in the body's fibrous (connective) tissues, which connect, support, and surround other bodily components and organs. Aggressive fibromatosis is most commonly known as a desmoid tumor because it resembles fibrosarcoma, a malignant (cancerous) tumor. However, it is deemed benign since it does not spread to other areas of the body (metastasize). The cells responsible for aggressive fibromatosis are the myofibroblasts. These tumors are difficult to treat as they can also spread in neighboring tissues. Deep desmoids are more aggressive than superficial desmoids (abdominal, extra-abdominal, mesenteric). These tumors have the appearance of thick scar tissue. Surgery has traditionally been the treatment of choice for desmoid tumors.
[7876]
Aggressive Fibromatosis Market Dynamics
Based on the market analysis, the global aggressive fibromatosis market is expected to rise with notable revenue growth during the forecast period. One common trend responsible for the overall revenue growth of the global aggressive fibromatosis treatment market is the increasing use of precision medicine, which involves personalized treatment to the genetic makeup of the tumor and the individual patient. This approach is becoming more common for a variety of cancers. It could potentially be applied to the treatment of aggressive fibromatosis as well. In terms of surgical treatments for aggressive fibromatosis, there is a growing trend toward using minimally invasive surgical techniques. These techniques typically involve smaller incisions and shorter hospital stays and may lead to faster patient recovery times. The incidence of aggressive fibromatosis has been increasing worldwide, leading to increased demand for treatment options. The development of advanced diagnostic techniques, such as molecular and genetic testing, has facilitated the early and accurate diagnosis of aggressive fibromatosis.
Additionally, awareness and education about aggressive fibromatosis among patients, physicians, and the rest of the population have improved, leading to earlier detection and treatment of the disease. There has been significant progress in the development of new treatments for aggressive fibromatosis, including surgery, radiation therapy, chemotherapy, and targeted therapies. This has led to a greater range of treatment options for patients. Governments and private organizations are investing heavily in healthcare, which has led to improved access to healthcare facilities, including diagnostic and treatment options, for patients with aggressive fibromatosis. These overall contribute to the market revenue growth of the global aggressive fibromatosis.
One of the most significant restraining factors in the global aggressive fibromatosis market is the high expense of surgeries. Aggressive fibromatosis and accompanying disorders are highly expensive to treat and/or manage. The market revenue expansion can also be hampered by a lack of infrastructure in low- and middle-income economies. Several market issues can also provide a threat to the leading market players. This includes the cost of the diagnostics as well as the treatment options. High treatment and maintenance expenses for desmoid tumors and related disorders and a lack of infrastructure in middle and low-income countries may hamper the aggressive fibromatosis market revenue growth.
Aggressive Fibromatosis Market Ecosystem
The global aggressive fibromatosis market has been analyzed from four perspectives: treatment type, patient type, end user, and region.
Aggressive Fibromatosis Market by Treatment Type
[96756]
Based on treatment type, the global aggressive fibromatosis market is segmented into NSAIDs, radiation therapy, chemotherapy, medication, hormone therapy, and molecular targeted therapy.
Chemotherapy accounts for the largest revenue share in the global market. Chemotherapy drugs kill the tumor cells while also preventing them from growing, dividing, and reproducing. Chemotherapy for a desmoid tumor is normally administered as an outpatient treatment. Some of the medications used in chemotherapy and/or in combination are Methotrexate (Trexall); Vinblastine (Velban); Liposomal doxorubicin (Doxil); Doxorubicin, used alone or in combination with dacarbazine; Dacarbazine, only used in combination with doxorubicin; Vinorelbine, only used in combination with doxorubicin. Chemotherapy can also be used to treat a desmoid tumor that is aggressive and causes organ damage or causing symptoms. Chemotherapy side effects vary depending on the medicine and the amount used. However, they might include exhaustion, infection risk, nausea and vomiting, hair loss, loss of appetite, and diarrhea. These adverse effects normally fade away once the therapy is completed. In rare cases, long-term problems affect the heart or kidneys or cause cancer.
Similarly, NSAIDs are also highly utilized in the treatment of aggressive fibromatosis. Nonsteroidal anti-inflammatory medicines can occasionally help reduce a desmoid tumor while alleviating pain and swelling. These medications include Celecoxib (Celebrex), ibuprofen, indomethacin (Tivorbex), naproxen, and sulindac. These might be used with other therapies, such as hormone therapy.
The targeted molecular therapy segment holds a significant share in the global desmoid tumor market because this type of therapy is highly effective in treating desmoid tumors. Targeted molecular therapy involves the use of drugs that target specific molecules or signaling pathways involved in the growth and spread of cancer cells. In the case of desmoid tumors, the main molecular target is the beta-catenin protein, which is involved in developing these tumors. Several drugs have been developed that specifically target the beta-catenin protein, including sorafenib, pazopanib, imatinib, and others. In addition, molecular targeted therapy is generally well-tolerated by patients, with few side effects compared to traditional chemotherapy. This makes it an attractive treatment option for patients with desmoid tumors, particularly those who may not be candidates for surgery.
Aggressive Fibromatosis Market by Patient Type
Based on patient type, the global aggressive fibromatosis market is segmented into pediatric and adult.
The incidence of aggressive fibromatosis is more commonly found in adults than in children. Therefore, the adult segment dominates the global aggressive fibromatosis market accounting for the largest market revenue share. Aggressive fibromatosis is often associated with certain medical conditions. One of them is familial adenomatous polyposis (FAP). This hereditary condition causes multiple polyps to form in the colon and rectum. FAP is more common in adults than children, which further contributes to the dominance of the adult segment in the global aggressive fibromatosis market. Moreover, as the population ages, the incidence of aggressive fibromatosis in the adult population is likely to increase. Thus, the adult segment will continue dominating the global desmoid tumor market during the forecast period.
Aggressive Fibromatosis Market by End User
Based on the end user, the global aggressive fibromatosis market can be further segmented into hospitals & clinics, specialty clinics, and others.
Hospitals & clinics dominate the global aggressive fibromatosis market in terms of revenue share as they are typically the primary location where aggressive fibromatosis is diagnosed and treated. When a patient presents with symptoms of aggressive fibromatoses, such as pain, swelling, or a lump, this results in a frequent visit to a hospital for evaluation and testing. Moreover, hospitals provide the necessary equipment and medical expertise to diagnose and treat aggressive fibromatosis. They can also provide access to specialized treatments and procedures, such as surgery or radiation therapy. In addition, hospitals may work closely with other healthcare providers, such as oncologists or radiologists, and research institutes to provide coordinated and experimental care for patients with aggressive fibromatosis.
Aggressive Fibromatosis Market by Region
Based on the region, the global aggressive fibromatosis market can be further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates the global market with the largest revenue share. The incidence of aggressive fibromatosis is higher in North America than in other regions. This can be caused due to genetic or environmental factors or differences in diagnosis and reporting. The well-developed healthcare infrastructure of North America includes advanced diagnostic and treatment technologies, highly skilled healthcare professionals, and comprehensive insurance coverage. This may have enabled better diagnosis and management of aggressive fibromatosis, leading to higher demand for related products and services. North America is the center for many leading biotech and pharmaceutical companies, research institutions, and academic medical centers that research desmoid tumors and develop new therapies. This may have led to the development of innovative treatments and products in high market demand.
The Asia Pacific region is expected to register a significantly growing CAGR in the global market. The incidence of desmoid tumors has been on the rise in Asia, with the highest incidence reported in Japan. This increase in prevalence has driven demand for effective treatments, leading to growth in terms of revenue share in the desmoid tumor market. Governments in the Asia Pacific region have been investing heavily in healthcare infrastructure and increasing healthcare expenditure. This has led to better access to healthcare facilities and increased awareness of rare diseases such as desmoid tumors. Technological advancements in medical imaging and surgical procedures have made it possible to diagnose and treat desmoid tumors more effectively. This has led to increased adoption of these technologies in Asia Pacefic, further driving regional revenue growth. Pharmaceutical companies are investing heavily in researching and developing new treatments for desmoid tumors.
Competitive Landscape
The prominent players operating in the global aggressive fibromatosis market are:
Strategic Development
Aggressive fibromatosis, also known as a desmoid tumor, is an uncommon type of fibrous tumor with low-grade malignancy and a high recurrence potential, with minimum chances of reoccurrence.
Takeda Pharmaceuticals Inc., Novartis AG, AbbVie Inc., and Bayer AG are the key players in the global aggressive fibromatosis market.
The chemotherapy segment accounts for the largest revenue share in the global aggressive fibromatosis market.
Asia Pacific region is expected to observe the fastest global aggressive fibromatosis market growth in the forecast period.
The high cost of treatment and lack of awareness among the population is the major factors restraining market revenue growth.
*Insights on financial performance are subject to the availability of information in the public domain